Monthly
US$200
Billed every month
Sign in to subscribeDoxazosin Mesylate Extended Release Tablets
As of 13 November 2026, for Doxazosin Mesylate Extended Release Tablets, 3 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 11 holders.
Companies, stages and changes, with each record available on this page.
Listed in the US FDA Orange Book as CARDURA XL (NDA 021269, VIATRIS SPECIALTY LLC).
No changes recorded by this site in the last 90 days
Complete CDE snapshot: 2026/11/13 06:42
Current coverage may be incomplete
US Orange Book listing
The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.
Orange Book source export date: 2026/11/06. Version: 2026-11-06.
Showing 2 of 2 distinct brand names.
A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.
Verified official English dosage form: Extended Release Tablets. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.
Same dosage form
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| CARDURA XL | VIATRIS SPECIALTY LLC | NDA 021269 · Product no. 001, 002 | TABLET, EXTENDED RELEASE | ORAL | HUMAN PRESCRIPTION DRUG | 2005/02/22 |
Other dosage forms of the same ingredient
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| CARDURA | VIATRIS SPECIALTY LLC | NDA 019668 · Product no. 001, 002, 003, 004 | TABLET | ORAL | HUMAN PRESCRIPTION DRUG | 1990/11/02 |
Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Catalogue holders11View records ↓
Under-review filings3View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers12View records ↓
API companies with A status14View records ↓
Chemical-drug catalogue
Loaded records: 11 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 9 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Henan Fu Sen Pharma Co., Ltd. romanized | Zi Bo Wan Jie Pharmaceutical Co., Ltd. romanized | 国药准字H20265126 | 2026/07/08 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H20264172 | 2026/04/29 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Hefei Hua Fang Pharmaceuticals Technology Co., Ltd. romanized | Hefei Si Pu Rui Pharma Co., Ltd. romanized | 国药准字H20263175 | 2026/01/20 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Nanjing Yi Heng Pharmaceutical Co., Ltd. romanized | Nanjing Yi Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20254756 | 2025/06/30 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Sichuan Kelun Pharmaceutical Co., Ltd. | Sichuan Kelun Pharmaceutical Co., Ltd. | 国药准字H20253807 | 2025/04/01 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| TIANJIN LISHENG PHARMACEUTICAL CO., LTD | TIANJIN LISHENG PHARMACEUTICAL CO., LTD | 国药准字H20244353 | 2024/06/28 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Hua Run Shuang He Li Min Pharma (Jinan) Co., Ltd. romanized | Hua Run Shuang He Li Min Pharma (Jinan) Co., Ltd. romanized | 国药准字H20243226 | 2024/02/23 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Hefei Li Fang Pharmaceutical Co., Ltd. romanized | Hefei Li Fang Pharmaceutical Co., Ltd. romanized | 国药准字H20103571 | 2023/12/13 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Le Pu Pharmaceutical Technology Co., Ltd. romanized | Le Pu Pharmaceutical Technology Co., Ltd. romanized | 国药准字H20233964 | 2023/07/25 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangxi Shan Xiang Pharma Co., Ltd. romanized | Jiangxi Shan Xiang Pharma Co., Ltd. romanized | 国药准字H20233967 | 2023/07/25 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Pfizer Pharma PFE GmbH | Pfizer Pharmaceuticals LLC | H20170174;H20170175 | 2001/06/29 | 4mg | Imported originator drug | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 12 distinct approval numbers and 12 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| TIANJIN LISHENG PHARMACEUTICAL CO., LTD | 国药准字H20244353 | See source | Category B | XC02CAD177A010010100886 | NHSA |
| Nanjing Yi Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20254756 | See source | Category B | XC02CAD177A010010101605 | NHSA |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 国药准字H20253807 | See source | Category B | XC02CAD177A010010102180 | NHSA |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H20264172 | See source | Category B | XC02CAD177A010010102763 | NHSA |
| Henan Fu Sen Pharma Co., Ltd. romanized | 国药准字H20265126 | See source | Category B | XC02CAD177A010010103020 | NHSA |
| Hua Run Shuang He Li Min Pharma (Jinan) Co., Ltd. romanized | 国药准字H20243226 | See source | Category B | XC02CAD177A010010103973 | NHSA |
| Hefei Li Fang Pharmaceutical Co., Ltd. romanized | 国药准字H20103571 | See source | Category B | XC02CAD177A010010104394 | NHSA |
| Jiangxi Shan Xiang Pharma Co., Ltd. romanized | 国药准字H20233967 | See source | Category B | XC02CAD177A010010105345 | NHSA |
| Pfizer Pharma PFE GmbH | 国药准字J20140130 | 4mg | Category B | XC02CAD177A010010178715 | NHSA |
| Le Pu Pharmaceutical Technology Co., Ltd. romanized | 国药准字H20233964 | See source | Category B | XC02CAD177A010010182919 | NHSA |
| Hefei Hua Fang Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263175 | See source | Category B | XC02CAD177A010010183480 | NHSA |
| Nanjing Yi Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20254756 | See source | Category B | XC02CAD177A010010201605 | NHSA |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H20264172 | See source | Category B | XC02CAD177A010010202763 | NHSA |
| Hua Run Shuang He Li Min Pharma (Jinan) Co., Ltd. romanized | 国药准字H20243226 | See source | Category B | XC02CAD177A010010203973 | NHSA |
| Jiangxi Shan Xiang Pharma Co., Ltd. romanized | 国药准字H20233967 | See source | Category B | XC02CAD177A010010205345 | NHSA |
| Viatris Pharma GmbH | 国药准字HJ20170175 | 4mg | Category B | XC02CAD177A010010278715 | NHSA |
| Le Pu Pharmaceutical Technology Co., Ltd. romanized | 国药准字H20233964 | See source | Category B | XC02CAD177A010010282919 | NHSA |
| Nanjing Yi Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20254756 | See source | Category B | XC02CAD177A010010301605 | NHSA |
| Hua Run Shuang He Li Min Pharma (Jinan) Co., Ltd. romanized | 国药准字H20243226 | See source | Category B | XC02CAD177A010010303973 | NHSA |
| Jiangxi Shan Xiang Pharma Co., Ltd. romanized | 国药准字H20233967 | See source | Category B | XC02CAD177A010010305345 | NHSA |
| Le Pu Pharmaceutical Technology Co., Ltd. romanized | 国药准字H20233964 | See source | Category B | XC02CAD177A010010382919 | NHSA |
| Nanjing Yi Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20254756 | See source | Category B | XC02CAD177A010010401605 | NHSA |
| Hua Run Shuang He Li Min Pharma (Jinan) Co., Ltd. romanized | 国药准字H20243226 | See source | Category B | XC02CAD177A010010403973 | NHSA |
| Hefei Li Fang Pharmaceutical Co., Ltd. romanized | 国药准字H20103571 | See source | Category B | XC02CAD177A010020104394 | NHSA |
| Le Pu Pharmaceutical Technology Co., Ltd. romanized | 国药准字H20233964 | See source | Category B | XC02CAD177A010020182919 | NHSA |
| Hefei Hua Fang Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20263175 | See source | Category B | XC02CAD177A010020183480 | NHSA |
| Hefei Li Fang Pharmaceutical Co., Ltd. romanized | 国药准字H20103571 | See source | Category B | XC02CAD177A010020204394 | NHSA |
| Hefei Li Fang Pharmaceutical Co., Ltd. romanized | 国药准字H20103571 | See source | Category B | XC02CAD177A010030104394 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 3 filings and 3 distinct first applicants.
Generic 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Changzhou Pharmaceutical Factory Co., Ltd. romanized | CYHS2502476 | Generic | 2025/07/11 | Not stated by source | CDE |
| Hui Zhi Pharmaceutical (Da Lian) Co., Ltd. romanized | CYHS2600416 | Generic | 2026/02/10 | Not stated by source | CDE |
| Shanghai Xin Yi Bai Lu Da Pharma Co., Ltd. romanized | CYHS2600147 | Generic | 2026/01/13 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Hui Zhi Pharmaceutical (Da Lian) Co., Ltd. romanized | CYHS2600416 | Generic | 2026/02/10 | Not stated by source | CDE |
| Shanghai Xin Yi Bai Lu Da Pharma Co., Ltd. romanized | CYHS2600147 | Generic | 2026/01/13 | Not stated by source | CDE |
API registrations
Non-component matches: 14 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 甲磺酸多沙唑嗪 · No verified English name | Nifty Labs Private Limited | Y20250001113 | I | Exact ingredient | 2025/10/29 | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Viatris Pharma GmbH | Y20230001002 | A | Exact ingredient | 2026/02/24 | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Hebei Guo Long Pharmaceutical Co., Ltd. romanized | Y20220000910 | A | Exact ingredient | 2026/01/28 | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Apitoria Pharma Private Limited | Y20210000707 | A | Exact ingredient | 2025/12/12 | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Hefei Li Fang Pharmaceutical Co., Ltd. romanized | Y20220000380 | A | Exact ingredient | 2026/07/16 | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | 'Srini Pharmaceuticals Private Limited | Y20200000857 | A | Exact ingredient | 2023/02/23 | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Zhejiang Le Pu Pharma Co., Ltd. romanized | Y20190007511 | A | Exact ingredient | 2024/02/05 | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Yi Bin Hong Guang Pharmaceutical Factory romanized | Y20190005693 | A | Exact ingredient | — | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Kang Mei Pharma Co., Ltd. romanized | Y20190003931 | A | Exact ingredient | — | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Changzhou Pharmaceutical Factory Co., Ltd. romanized | Y20190003560 | A | Exact ingredient | 2025/05/07 | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Tao Sheng Pharmaceutical Co., Ltd. romanized | Y20190003173 | A | Exact ingredient | — | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Topfond Pharmaceutical Co., Ltd. | Y20190003031 | A | Exact ingredient | — | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Zhejiang Jin Hua Kang En Bei Biopharmaceutical Co., Ltd. romanized | Y20190002529 | A | Exact ingredient | — | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Zhejiang Di Er Pharma Co., Ltd. romanized | Y20190002528 | A | Exact ingredient | 2025/04/22 | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Zhejiang Xin Sai Ke Pharma Co., Ltd. romanized | Y20170000552 | A | Exact ingredient | 2024/05/06 | CDE |
| 甲磺酸多沙唑嗪 · No verified English name | Hefei Li Fang Pharmaceutical Co., Ltd. romanized | Y20170000322 | A | Exact ingredient | 2024/03/15 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/13 06:41
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Doxazosin Mesylate Extended Release Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy